Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology
Initial Results from Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Relapsed Multiple Myeloma Featured in Oral Presentations
SOUTH SAN FRANCISCO, Calif., November 25, 2008 /PRNewswire/ -- Proteolix, Inc., a leader in the discovery and development of novel therapeutics that target protein degradation pathways in cancer and autoimmune diseases, today announced that data from two ongoing Phase 2 clinical trials of carfilzomib in multiple myeloma will be presented at the upcoming 50th Annual Meeting of the American Society of Hematology (ASH). Carfilzomib is the first in a new class of specific proteasome inhibitors and is currently in multiple clinical trials for hematologic malignancies and solid tumors. This year's ASH conference will be held December 6-9, 2008 at the George Moscone Center in San Francisco, California.
Sundar Jagannath, M.D., Chief of the Multiple Myeloma Program, Bone Marrow and Blood Stem Cell Transplantation at St. Vincent's Comprehensive Cancer Center in New York will present initial results from Proteolix's Phase 2 study of carfilzomib for the treatment of patients with relapsed and refractory multiple myeloma during the Novel Therapies for Myeloma and Related Disorders session at 7:00 a.m. on Tuesday, December 9, 2008. This ongoing Phase 2 trial is an open-label multi-center study of single-agent carfilzomib in patients who have previously failed at least two prior treatments, containing bortezomib and either lenalidomide or thalidomide, and are refractory to their last treatment. Data from a second ongoing Phase 2 clinical trial of single-agent carfilzomib in relapsed multiple myeloma patients (stratified by prior therapy with bortezomib) will be presented immediately thereafter at 7:15 a.m. by Ravi Vij, M.D., Associate Professor of Medicine, Division of Oncology, Section of Bone Marrow Transplantation, School of Medicine.
In addition to the oral presentations, the company will have several poster presentations highlighting the results of preclinical studies that further characterize the mechanism and safety profile of carfilzomib. Proteolix will also have a poster presentation on the preclinical pharmacology and characterization of its oral proteasome inhibitor known as PR-047.
A complete list of the company's oral and poster presentations at the ASH meeting follows:
Oral Presentations -- Tuesday, December 9, 2008
Session: Novel Therapies for Myeloma and Related Disorders
-- 7:00 a.m. PST: Initial Results of PX-171-003, An Open-Label,
Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with
Relapsed and Refractory Multiple Myeloma (MM) (Abstract #864)
-- 7:15 a.m. PST: Initial Results of PX-171-004, An Open-Label,
Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with
Relapsed Myeloma (MM) (Abstract #865)
Location: Moscone Center, Gateway Ballroom 103-South
Poster Presentations
Sunday, December 7, 2008, 6:00 p.m. -- 8:00 p.m. PST
Session: Molecular Pharmacology, Drug Resistance Poster II
-- Non-Proteasomal Targets of Proteasome Inhibitors Bortezomib and
Carfilzomib (Abstract #2657)
Session: Myeloma -- Pathophysiology and Preclinical Studies Excluding
Therapy Poster II
-- The Selective Proteasome Inhibitor Carfilzomib is Well Tolerated in
Experimental Animals with Dose Intensive Administration (Abstract
#2765)
Location: Moscone Center Hall A
Monday, December 8, 2008, 5:30 p.m. -- 7:30 p.m. PST
Session: Myeloma -- Pathophysiology and Preclinical Studies Excluding
Therapy Poster III
-- Induction of Sustained Early G1 Arrest by Selective Inhibition of
CDK4 and CDK6 Primes Myeloma Cells for Synergistic Killing by
Proteasome Inhibitors Carfilzomib and PR-047 (Abstract #3670)
-- Preclinical Pharmacology and in vitro Characterization of PR-047, An
Oral Inhibitor of the 20S Proteasome (Abstract #3671)
Location: Moscone Center Hall A
About Proteolix
Proteolix, Inc. is a privately-held biopharmaceutical company, headquartered in South San Francisco, dedicated to discovering, developing and commercializing novel therapeutics that target protein degradation pathways for cancer and autoimmune diseases. Proteolix's lead product, carfilzomib (PR-171), the first in a new class of highly specific proteasome inhibitors, is currently in multiple Phase 2 clinical studies to evaluate its safety and efficacy in hematologic and solid tumor malignancies. Proteolix is also developing a pipeline of novel proteasome inhibitors, including an oral proteasome inhibitor and a selective immunoproteasome inhibitor. For additional information on Proteolix, please visit http://www.proteolix.com.
Contact information
Investors: Media Inquiries:
Matthew Ferguson BCC Partners
Chief Financial Officer Karen L. Bergman or Michelle Corral
650-266-2825 650-575-1509 or 415-794-8662
investors@proteolix.com
CONTACT: Investors, Matthew Ferguson, Chief Financial Officer ofProteolix, Inc., +1-650-266-2825, ; Media, Karen L.Bergman or Michelle Corral both of BCC Partners, +1-650-575-1509, or+1-415-794-8662, for Proteolix, Inc. investors@proteolix.com
Web site: http://www.proteolix.com/
Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: November 2008
